Increase Cardiovascular Event in Patient with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
DOI:
https://doi.org/10.21776/ub/hsj.2024.005.03.5Keywords:
Diabetes Mellitus, Coronary Artery Disease, Percutaneous Coronary InterventionAbstract
Diabetes mellitus (DM) associated with increase major risk factors of cardiovascular disease, such as peripheral arteriopathy, ischemic heart disease, or cerebrovascular accident. The Framingham study showed that patient with DM considerably increase coronary artery disease (CAD), particularly in old patient and women. Prevalence of DM is rising and cardiovascular mortality associated with DM is the main problem in the world. Additionally, there is a higher death rate among DM patients following a myocardial infarction with complications, such as stent thrombosis, instent restenosis, and no reflow phenomenon can worse overall long term prognosis with CAD. This review c onsiders the mechanism for diabetes mellitus in CAD patient, expecially patient with DM can increase risk of major complication in patient CAD undergoing percutaneous coronary intervention (PCI).
References
Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014;32(3):439-455. doi:10.1016/j.ccl.2014.04.001
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus. Circulation. 2016;133(24):2459-2502. doi:10.1161/CIRCULATIONAHA.116.022194
Flaherty JD, Davidson CJ. Diabetes and Coronary Revascularization. Vol 293.; 2005. www.jama.comwww.jama.com
Zamora A. Prognosis of Diabetic Patients with Coronary Heart Disease. Rev Esp Cardiol . Published online 2002:751-762.
Diabetology C, Aronson D, Rayfield EJ. Cardiovascular Diabetology How Hyperglycemia Promotes Atherosclerosis: Molecular Mechanisms.; 2002. http://www.cardiab.com/content/1/1/1
Li Y, Li XW, Zhang YH, et al. Prognostic significance of the hemoglobin A1c level in non-diabetic patients undergoing percutaneous coronary intervention: A meta-analysis. Chin Med J (Engl). 2020;133(18):2229-2235. doi:10.1097/CM9.0000000000001029
Kassaian SE, Goodarzynejad H, Boroumand MA, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol. 2012;11. doi:10.1186/1475-2840-11-82
Pechlivani N, Ajjan RA. Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. Front Cardiovasc Med. 2018;5. doi:10.3389/fcvm.2018.00001
Khalfallah M, Maria DA, Allaithy A. Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Glob Heart. 2022;17(1). doi:10.5334/GH.1111
Nusca A, Piccirillo F, Bernardini F, et al. Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. Int J Mol Sci. 2022;23(13). doi:10.3390/ijms23137261
Kruger D. Neo-intimal hyperplasia, diabetes and endovascular injury. Cardiovasc J Afr. 2012;23(9):507-511. doi:10.5830/CVJA-2012-019
Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32(7):1866-1873. doi:10.1016/S0735-1097(98)00467-7
Indolfi C, Torella D, Cavuto L, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation. 2001;103(24):2980-2986. doi:10.1161/01.CIR.103.24.2980
Wilson S, Mone P, Kansakar U, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21(1). doi:10.1186/s12933-022-01460-5
Yang CD, Shen Y, Lu L, et al. Visit-to-visit HbA1cvariability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention. Cardiovasc Diabetol. 2020;19(1). doi:10.1186/s12933-020-01111-7
Bittl JA. Percutaneous Coronary Interventions in the Diabetic Patient. Circ Cardiovasc Interv. 2015;8(4). doi:10.1161/CIRCINTERVENTIONS.114.001944
Endokrinologi Indonesia PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE P. PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI.
Leon BM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246. doi:10.4239/wjd.v6.i13.1246
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. Published online August 25, 2023. doi:10.1093/eurheartj/ehad192
Capodanno D, Angiolillo DJ. Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients with Coronary Artery Disease and Diabetes Mellitus. Circulation. 2020;142(22):2172-2188. doi:10.1161/CIRCULATIONAHA.120.045465
Schubert M, Hansen S, Leefmann J, Guan K. Repurposing Antidiabetic Drugs for Cardiovascular Disease. Front Physiol. 2020;11. doi:10.3389/fphys.2020.568632
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).